A single protein may be holding back CAR T cancer therapy

Researchers from Columbia University and University Hospital Tübingen have discovered a protein that appears to play a major role in weakening CAR T cells over time. By disabling the protein, known as NFIL3, the scientists found that these engineered immune cells remained active longer and were better able to attack tumors. The findings, published in Cancer Discovery, could help improve CAR T-cell therapy, particularly against solid tumors that have proven difficult to tre...